ID   TYRO3_HUMAN             Reviewed;         890 AA.
AC   Q06418; O14953; Q86VR3;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-OCT-2022, entry version 208.
DE   RecName: Full=Tyrosine-protein kinase receptor TYRO3;
DE            EC=2.7.10.1;
DE   AltName: Full=Tyrosine-protein kinase BYK;
DE   AltName: Full=Tyrosine-protein kinase DTK;
DE   AltName: Full=Tyrosine-protein kinase RSE;
DE   AltName: Full=Tyrosine-protein kinase SKY;
DE   AltName: Full=Tyrosine-protein kinase TIF;
DE   Flags: Precursor;
GN   Name=TYRO3; Synonyms=BYK, DTK, RSE, SKY, TIF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7511603; DOI=10.1016/s0021-9258(17)34118-2;
RA   Mark M.R., Scadden D.T., Wang Z., Gu Q., Goddard A., Godowski P.J.;
RT   "RSE, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is
RT   expressed at high levels in the brain.";
RL   J. Biol. Chem. 269:10720-10728(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8108112;
RA   Ohashi K., Mizuno K., Kuma K., Miyata T., Nakamura T.;
RT   "Cloning of the cDNA for a novel receptor tyrosine kinase, Sky,
RT   predominantly expressed in brain.";
RL   Oncogene 9:699-705(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT VAL-815.
RC   TISSUE=Brain;
RX   PubMed=7857658; DOI=10.3109/08977199409001055;
RA   Crosier K.E., Hall L.R., Lewis P.M., Morris C.M., Wood C.R., Morris J.C.,
RA   Crosier P.S.;
RT   "Isolation and characterization of the human DTK receptor tyrosine
RT   kinase.";
RL   Growth Factors 11:137-144(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=9175267; DOI=10.1016/s0248-4900(97)86830-x;
RA   Kajii Y., Ninomiya D., Kato M., Mizuguchi M., Saji M., Katsumoto T.,
RA   Ohno K., Takashima S., Onodera K.;
RT   "A tyrosine kinase-like molecule is localized in the nuclear membrane of
RT   neurons: hippocampal behavior under stress.";
RL   Biol. Cell 88:45-54(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS LEU-21; SER-542;
RP   MET-819 AND GLY-824.
RC   TISSUE=Skin, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 519-720.
RX   PubMed=8262388; DOI=10.1016/0378-1119(93)90109-g;
RA   Polvi A., Armstrong E., Lai C., Lemke G., Huebner K., Spritz R.A.,
RA   Giuda L.C., Nicholls R.D., Alitalo K.;
RT   "The human TYRO3 gene and pseudogene are located in chromosome 15q14-q25.";
RL   Gene 134:289-293(1993).
RN   [7]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=7537495; DOI=10.1006/bbrc.1995.1549;
RA   Toshima J., Ohashi K., Iwashita S., Mizuno K.;
RT   "Autophosphorylation activity and association with Src family kinase of Sky
RT   receptor tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 209:656-663(1995).
RN   [8]
RP   INTERACTION WITH GAS6.
RX   PubMed=7634325; DOI=10.1016/0092-8674(95)90424-7;
RA   Godowski P.J., Mark M.R., Chen J., Sadick M.D., Raab H., Hammonds R.G.;
RT   "Reevaluation of the roles of protein S and Gas6 as ligands for the
RT   receptor tyrosine kinase Rse/Tyro 3.";
RL   Cell 82:355-358(1995).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=16737840; DOI=10.1016/j.cytogfr.2006.04.004;
RA   Hafizi S., Dahlback B.;
RT   "Signalling and functional diversity within the Axl subfamily of receptor
RT   tyrosine kinases.";
RL   Cytokine Growth Factor Rev. 17:295-304(2006).
RN   [10]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17005688; DOI=10.1128/jvi.01157-06;
RA   Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K., Irimura T.,
RA   Jones S., Feldmann H., Kawaoka Y.;
RT   "Tyro3 family-mediated cell entry of Ebola and Marburg viruses.";
RL   J. Virol. 80:10109-10116(2006).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=18421305; DOI=10.1038/nri2303;
RA   Lemke G., Rothlin C.V.;
RT   "Immunobiology of the TAM receptors.";
RL   Nat. Rev. Immunol. 8:327-336(2008).
RN   [12]
RP   FUNCTION IN PLATELET ACTIVATION.
RX   PubMed=20546121; DOI=10.1111/j.1538-7836.2010.03935.x;
RA   Cosemans J.M., Van Kruchten R., Olieslagers S., Schurgers L.J.,
RA   Verheyen F.K., Munnix I.C., Waltenberger J., Angelillo-Scherrer A.,
RA   Hoylaerts M.F., Carmeliet P., Heemskerk J.W.;
RT   "Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human
RT   and murine platelet activation and thrombus stabilization.";
RL   J. Thromb. Haemost. 8:1797-1808(2010).
RN   [13]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=22156524; DOI=10.1128/jvi.06451-11;
RA   Shimojima M., Stroher U., Ebihara H., Feldmann H., Kawaoka Y.;
RT   "Identification of cell surface molecules involved in dystroglycan-
RT   independent Lassa virus cell entry.";
RL   J. Virol. 86:2067-2078(2012).
RN   [14]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=22673088; DOI=10.1292/jvms.12-0176;
RA   Shimojima M., Kawaoka Y.;
RT   "Cell surface molecules involved in infection mediated by lymphocytic
RT   choriomeningitis virus glycoprotein.";
RL   J. Vet. Med. Sci. 74:1363-1366(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-466 AND SER-818, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   FUNCTION (MICROBIAL INFECTION), AND REVIEW.
RX   PubMed=25277499; DOI=10.1016/j.virol.2014.09.009;
RA   Moller-Tank S., Maury W.;
RT   "Phosphatidylserine receptors: enhancers of enveloped virus entry and
RT   infection.";
RL   Virology 468:565-580(2014).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.96 ANGSTROMS) OF 41-222, SUBUNIT, INTERACTION WITH
RP   GAS6, MUTAGENESIS OF ILE-99, AND DISULFIDE BONDS.
RX   PubMed=14623883; DOI=10.1074/jbc.m311750200;
RA   Heiring C., Dahlbaeck B., Muller Y.A.;
RT   "Ligand recognition and homophilic interactions in Tyro3: structural
RT   insights into the Axl/Tyro3 receptor tyrosine kinase family.";
RL   J. Biol. Chem. 279:6952-6958(2004).
RN   [18]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-831.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from the
CC       extracellular matrix into the cytoplasm by binding to several ligands
CC       including TULP1 or GAS6. Regulates many physiological processes
CC       including cell survival, migration and differentiation. Ligand binding
CC       at the cell surface induces dimerization and autophosphorylation of
CC       TYRO3 on its intracellular domain that provides docking sites for
CC       downstream signaling molecules. Following activation by ligand,
CC       interacts with PIK3R1 and thereby enhances PI3-kinase activity.
CC       Activates the AKT survival pathway, including nuclear translocation of
CC       NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated
CC       genes. TYRO3 signaling plays a role in various processes such as neuron
CC       protection from excitotoxic injury, platelet aggregation and
CC       cytoskeleton reorganization. Also plays an important role in inhibition
CC       of Toll-like receptors (TLRs)-mediated innate immune response by
CC       activating STAT1, which selectively induces production of suppressors
CC       of cytokine signaling SOCS1 and SOCS3. {ECO:0000269|PubMed:20546121}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and
CC       lymphocytic choriomeningitis virus, possibly through GAS6 binding to
CC       phosphatidyl-serine at the surface of virion envelope.
CC       {ECO:0000269|PubMed:22156524, ECO:0000269|PubMed:22673088,
CC       ECO:0000269|PubMed:25277499}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus,
CC       possibly through GAS6 binding to phosphatidyl-serine at the surface of
CC       virion envelope. {ECO:0000269|PubMed:17005688}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Monomer and homodimer. Interacts (via N-terminus) with
CC       extracellular ligands TULP1 and GAS6 (By similarity). Interacts with
CC       PIK3R1; this interaction increases PI3-kinase activity (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q06418; P62993: GRB2; NbExp=4; IntAct=EBI-3951628, EBI-401755;
CC       Q06418; P08238: HSP90AB1; NbExp=2; IntAct=EBI-3951628, EBI-352572;
CC       Q06418; Q9Y5K2: KLK4; NbExp=3; IntAct=EBI-3951628, EBI-10224152;
CC       Q06418; Q6A162: KRT40; NbExp=3; IntAct=EBI-3951628, EBI-10171697;
CC       Q06418; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-3951628, EBI-10172290;
CC       Q06418; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-3951628, EBI-10171774;
CC       Q06418; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-3951628, EBI-10172052;
CC       Q06418; Q9BYR5: KRTAP4-2; NbExp=3; IntAct=EBI-3951628, EBI-10172511;
CC       Q06418; P26371: KRTAP5-9; NbExp=5; IntAct=EBI-3951628, EBI-3958099;
CC       Q06418; Q9BYQ4: KRTAP9-2; NbExp=3; IntAct=EBI-3951628, EBI-1044640;
CC       Q06418; Q99750: MDFI; NbExp=3; IntAct=EBI-3951628, EBI-724076;
CC       Q06418; B2RUY7: VWC2L; NbExp=3; IntAct=EBI-3951628, EBI-11747707;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein.
CC   -!- TISSUE SPECIFICITY: Abundant in the brain and lower levels in other
CC       tissues.
CC   -!- PTM: Autophosphorylated.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA21781.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TYRO3ID42739ch15q15.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U05682; AAA19236.1; -; mRNA.
DR   EMBL; D17517; BAA04467.1; -; mRNA.
DR   EMBL; U18934; AAC50070.1; -; mRNA.
DR   EMBL; D50479; BAA21781.1; ALT_INIT; mRNA.
DR   EMBL; BC049368; AAH49368.1; -; mRNA.
DR   EMBL; BC051756; AAH51756.1; -; mRNA.
DR   EMBL; X72886; CAA51396.1; -; mRNA.
DR   CCDS; CCDS10080.1; -.
DR   PIR; A53743; A53743.
DR   PIR; I38912; I38912.
DR   RefSeq; NP_001317193.1; NM_001330264.1.
DR   RefSeq; NP_006284.2; NM_006293.3.
DR   PDB; 1RHF; X-ray; 1.96 A; A/B=41-222.
DR   PDBsum; 1RHF; -.
DR   AlphaFoldDB; Q06418; -.
DR   SMR; Q06418; -.
DR   BioGRID; 113152; 35.
DR   IntAct; Q06418; 121.
DR   MINT; Q06418; -.
DR   STRING; 9606.ENSP00000263798; -.
DR   BindingDB; Q06418; -.
DR   ChEMBL; CHEMBL5314; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q06418; -.
DR   GuidetoPHARMACOLOGY; 1836; -.
DR   GlyConnect; 1982; 8 N-Linked glycans (5 sites).
DR   GlyGen; Q06418; 7 sites, 8 N-linked glycans (5 sites).
DR   iPTMnet; Q06418; -.
DR   PhosphoSitePlus; Q06418; -.
DR   BioMuta; TYRO3; -.
DR   DMDM; 1717829; -.
DR   EPD; Q06418; -.
DR   jPOST; Q06418; -.
DR   MassIVE; Q06418; -.
DR   MaxQB; Q06418; -.
DR   PaxDb; Q06418; -.
DR   PeptideAtlas; Q06418; -.
DR   PRIDE; Q06418; -.
DR   ProteomicsDB; 58444; -.
DR   Antibodypedia; 2066; 778 antibodies from 34 providers.
DR   DNASU; 7301; -.
DR   Ensembl; ENST00000263798.8; ENSP00000263798.3; ENSG00000092445.12.
DR   GeneID; 7301; -.
DR   KEGG; hsa:7301; -.
DR   MANE-Select; ENST00000263798.8; ENSP00000263798.3; NM_006293.4; NP_006284.2.
DR   UCSC; uc001zof.3; human.
DR   CTD; 7301; -.
DR   DisGeNET; 7301; -.
DR   GeneCards; TYRO3; -.
DR   HGNC; HGNC:12446; TYRO3.
DR   HPA; ENSG00000092445; Tissue enhanced (brain, ovary).
DR   MIM; 600341; gene.
DR   neXtProt; NX_Q06418; -.
DR   OpenTargets; ENSG00000092445; -.
DR   PharmGKB; PA37097; -.
DR   VEuPathDB; HostDB:ENSG00000092445; -.
DR   eggNOG; ENOG502QRYR; Eukaryota.
DR   GeneTree; ENSGT00940000155879; -.
DR   InParanoid; Q06418; -.
DR   OMA; VRCTNAL; -.
DR   OrthoDB; 263089at2759; -.
DR   PhylomeDB; Q06418; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q06418; -.
DR   SignaLink; Q06418; -.
DR   SIGNOR; Q06418; -.
DR   BioGRID-ORCS; 7301; 43 hits in 1108 CRISPR screens.
DR   ChiTaRS; TYRO3; human.
DR   EvolutionaryTrace; Q06418; -.
DR   GeneWiki; TYRO3; -.
DR   GenomeRNAi; 7301; -.
DR   Pharos; Q06418; Tchem.
DR   PRO; PR:Q06418; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q06418; protein.
DR   Bgee; ENSG00000092445; Expressed in frontal pole and 176 other tissues.
DR   ExpressionAtlas; Q06418; baseline and differential.
DR   Genevisible; Q06418; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005635; C:nuclear envelope; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0001618; F:virus receptor activity; IDA:FlyBase.
DR   GO; GO:0043277; P:apoptotic cell clearance; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; NAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0051649; P:establishment of localization in cell; IEA:Ensembl.
DR   GO; GO:0021885; P:forebrain cell migration; ISS:UniProtKB.
DR   GO; GO:0001779; P:natural killer cell differentiation; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0045824; P:negative regulation of innate immune response; ISS:UniProtKB.
DR   GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0070050; P:neuron cellular homeostasis; ISS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IEA:Ensembl.
DR   GO; GO:0042698; P:ovulation cycle; ISS:UniProtKB.
DR   GO; GO:0006909; P:phagocytosis; IBA:GO_Central.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; NAS:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; ISS:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:1903902; P:positive regulation of viral life cycle; IMP:FlyBase.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; ISS:UniProtKB.
DR   GO; GO:0032940; P:secretion by cell; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; ISS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00408; IGc2; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell adhesion; Cell membrane; Disulfide bond;
KW   Glycoprotein; Host cell receptor for virus entry; Host-virus interaction;
KW   Immunoglobulin domain; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase.
FT   SIGNAL          1..40
FT                   /evidence="ECO:0000255"
FT   CHAIN           41..890
FT                   /note="Tyrosine-protein kinase receptor TYRO3"
FT                   /id="PRO_0000024478"
FT   TOPO_DOM        41..429
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        430..450
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        451..890
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          41..128
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          139..220
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          227..320
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          325..416
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          518..790
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          815..837
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          851..871
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        655
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         524..532
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         550
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         466
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         681
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         685
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         686
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         804
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         818
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         869
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P55146"
FT   CARBOHYD        63
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        191
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        230
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        240
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        293
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        366
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        380
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        64..117
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:14623883"
FT   DISULFID        160..203
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:14623883"
FT   VARIANT         21
FT                   /note="P -> L (in dbSNP:rs17854578)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_045886"
FT   VARIANT         346
FT                   /note="I -> N (in dbSNP:rs12148316)"
FT                   /id="VAR_045887"
FT   VARIANT         542
FT                   /note="G -> S (in dbSNP:rs17857363)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_045888"
FT   VARIANT         815
FT                   /note="A -> V (in dbSNP:rs1042057)"
FT                   /evidence="ECO:0000269|PubMed:7857658"
FT                   /id="VAR_045889"
FT   VARIANT         819
FT                   /note="L -> M (in dbSNP:rs17854579)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_045890"
FT   VARIANT         824
FT                   /note="R -> G (in dbSNP:rs17857364)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_045891"
FT   VARIANT         831
FT                   /note="A -> T"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041876"
FT   MUTAGEN         99
FT                   /note="I->R: Abolishes dimerization."
FT                   /evidence="ECO:0000269|PubMed:14623883"
FT   CONFLICT        29..36
FT                   /note="Missing (in Ref. 3; AAC50070)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        285
FT                   /note="L -> F (in Ref. 4; BAA21781)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        293
FT                   /note="N -> I (in Ref. 4; BAA21781)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        341
FT                   /note="E -> V (in Ref. 4; BAA21781)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        812
FT                   /note="E -> D (in Ref. 4; BAA21781)"
FT                   /evidence="ECO:0000305"
FT   STRAND          50..55
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          60..68
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          74..78
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          85..94
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          97..106
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   HELIX           109..111
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          113..121
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          131..136
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          140..143
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          156..163
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          165..167
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          170..175
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          183..192
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          199..207
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          210..213
FT                   /evidence="ECO:0007829|PDB:1RHF"
FT   STRAND          217..221
FT                   /evidence="ECO:0007829|PDB:1RHF"
SQ   SEQUENCE   890 AA;  96905 MW;  F9EC675077C4E8F1 CRC64;
     MALRRSMGRP GLPPLPLPPP PRLGLLLAAL ASLLLPESAA AGLKLMGAPV KLTVSQGQPV
     KLNCSVEGME EPDIQWVKDG AVVQNLDQLY IPVSEQHWIG FLSLKSVERS DAGRYWCQVE
     DGGETEISQP VWLTVEGVPF FTVEPKDLAV PPNAPFQLSC EAVGPPEPVT IVWWRGTTKI
     GGPAPSPSVL NVTGVTQSTM FSCEAHNLKG LASSRTATVH LQALPAAPFN ITVTKLSSSN
     ASVAWMPGAD GRALLQSCTV QVTQAPGGWE VLAVVVPVPP FTCLLRDLVP ATNYSLRVRC
     ANALGPSPYA DWVPFQTKGL APASAPQNLH AIRTDSGLIL EWEEVIPEAP LEGPLGPYKL
     SWVQDNGTQD ELTVEGTRAN LTGWDPQKDL IVRVCVSNAV GCGPWSQPLV VSSHDRAGQQ
     GPPHSRTSWV PVVLGVLTAL VTAAALALIL LRKRRKETRF GQAFDSVMAR GEPAVHFRAA
     RSFNRERPER IEATLDSLGI SDELKEKLED VLIPEQQFTL GRMLGKGEFG SVREAQLKQE
     DGSFVKVAVK MLKADIIASS DIEEFLREAA CMKEFDHPHV AKLVGVSLRS RAKGRLPIPM
     VILPFMKHGD LHAFLLASRI GENPFNLPLQ TLIRFMVDIA CGMEYLSSRN FIHRDLAARN
     CMLAEDMTVC VADFGLSRKI YSGDYYRQGC ASKLPVKWLA LESLADNLYT VQSDVWAFGV
     TMWEIMTRGQ TPYAGIENAE IYNYLIGGNR LKQPPECMED VYDLMYQCWS ADPKQRPSFT
     CLRMELENIL GQLSVLSASQ DPLYINIERA EEPTAGGSLE LPGRDQPYSG AGDGSGMGAV
     GGTPSDCRYI LTPGGLAEQP GQAEHQPESP LNETQRLLLL QQGLLPHSSC
//
